Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Desensitization and Tachyphylaxis

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Baseline Human Metabolic Profiling and Risk of Death from COVID-19: Conceptualization of Multivariate Prediction Model Development via Retrospective Database Analysis in the United States Department of Veterans Affairs.

Journal of clinical medicine·2026

Same author

Expanding Horizons: Host Range Evolution and Treatment Strategies for Highly Pathogenic Avian Influenza H5N1 and H7N9.

Viruses·2026

Same author

Health Care Costs Associated With Norovirus at the Veterans Health Administration.

JAMA network open·2025

Same author

Bacteremic vs Nonbacteremic <i>Shigella</i> Infections in the United States Veterans Health Administration, 2000-2024.

Open forum infectious diseases·2025

Same author

Establishment of the Veterans Affairs SeqFORCE (Sequencing for Research Clinical and Epidemiology) program for SARS-CoV-2 whole-genome sequencing.

American journal of clinical pathology·2025

Same author

Epidemiology, Immunology and Clinical Characteristics of COVID-19 (EPIC<sup>3</sup>)-Database of a prospective longitudinal observational study within the Veterans Health Administration.

Frontiers in public health·2025

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

Sudden sensorineural hearing loss associated with vardenafil.

Amanda J Snodgrass¹, Heather M Campbell, David L Mace

¹Veterans Affairs Cooperative Studies Program, Clinical Research Pharmacy Coordinating Center, Albuquerque, NM 87106, USA.

Pharmacotherapy

|December 25, 2009

Summary

Phosphodiesterase type 5 (PDE-5) inhibitors, like vardenafil, may cause sudden hearing loss. A case study suggests vardenafil use led to unilateral hearing loss, which improved with corticosteroids.

Related Experiment Videos

Last Updated: Jun 17, 2026

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss

Published on: January 25, 2016

Area of Science:

Otolaryngology
Pharmacology
Urology

Background:

Phosphodiesterase type 5 (PDE-5) inhibitors (sildenafil, vardenafil, tadalafil) are widely used for erectile dysfunction and pulmonary hypertension.
While known for vision-related side effects, emerging evidence links PDE-5 inhibitors to auditory changes, including hearing loss.
This study investigates a potential association between vardenafil use and sudden sensorineural hearing loss.

Observation:

A 57-year-old male presented with unilateral sudden sensorineural hearing loss after vardenafil ingestion.
Audiometric evaluation confirmed mild-to-moderate hearing loss in the affected ear.
The patient received intravenous dexamethasone and oral prednisone, leading to significant hearing improvement.

Findings:

The Naranjo scale indicated a possible adverse drug reaction between vardenafil and sudden sensorineural hearing loss.
Analysis of FDA Adverse Event Reporting System data revealed other cases of hearing loss associated with PDE-5 inhibitors.
The temporal relationship strongly suggests vardenafil as a likely cause of the patient's hearing loss.

Implications:

PDE-5 inhibitor use should be considered in patients presenting with sudden sensorineural hearing loss.
This case adds to the growing body of evidence linking PDE-5 inhibitors to auditory adverse events.
Further research is warranted to elucidate the mechanisms and prevalence of hearing loss associated with PDE-5 inhibitors.